We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Ablation of Prostate Cancer by Thermal Rods

By HospiMedica staff writers
Posted on 14 Mar 2001
A new technique for using heat to ablate prostate cancer suggests it may be used alone as an alternative treatment option or at a lower temperature in combination with radiation.

The technique involves the percutaneous placement of small magnetic alloy rods into the prostate gland. More...
The rods are biocompatible implants, made of cobalt and palladium, which can be permanent. The patient with the implanted rods is then placed in an extracorporeal alternating magnetic field. As the rods resist the current, they heat but only to a temperature limit that was set during their manufacture.

In a study of the technique, researchers examined the effects of the rods placed within I cm of each other at various temperatures, finding that 70o C resulted in necrosis of cancerous prostate tissue. The treatment was well tolerated and could probably be performed in an outpatient setting, say the researchers. Since rods are permanently implanted, patients could be easily retreated when serum prostate-specific antigen (PSA) levels increase. The researchers also believe that treatment at hyperthermia temperatures in combination with radiation would be useful, since studies have shown heat enhances the effects of radiation.

The research team was headed by Robert D. Tucker, M.D., University of Iowa College of Medicine (Iowa City, IA, USA), whose earlier paper on the new technique was published in the August 2000 issue of the Journal of Endourology.

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.